SET and acute promyelocytic leukemia: ERK inhibition or heterogeneous nuclear ribonucleoprotein K knockdown decreases cell viability, increases all‐trans retinoic acid (ATRA)‐induced differentiation in acute promyelocytic leukemia (APL) ATRA‐resistant cells, and promotes SET cleavage.